Life Sciences

  • December 01, 2025

    UK To Raise Pharma Spending For US Tariff Protection

    The United States and United Kingdom announced a deal Monday that includes a commitment to exclude U.K. pharmaceutical imports from any future U.S. tariff actions while the U.K. will pay higher costs for certain drugs.

  • December 01, 2025

    FDA Withdraws Proposed Talc Cosmetics Testing Rule

    The U.S. Food and Drug Administration on Friday pulled back a proposed rule that would have required cosmetics manufacturers to test for asbestos in their talc products, saying it may have unintended consequences beyond those goods.

  • December 01, 2025

    Mich. Law Firm's Misrepresentation Voids Policy, Insurer Says

    An insurer asked a Michigan federal court to rescind and void a law firm's professional liability policy, saying the firm failed to disclose a potential malpractice claim arising out of its representation of the owner of medical services companies in a racketeering lawsuit and related whistleblower action.

  • December 01, 2025

    What MDL Judges Can Get Done With A New Civil Rule

    As the first federal procedure rule geared toward multidistrict litigation goes into effect, judges will have a new buffet of best practices to guide them, but little in the way of hand-tying mandates.

  • December 01, 2025

    Squire Patton Brings On DLA Piper Patent Litigator In SF

    Squire Patton Boggs LLP is growing its intellectual property team, announcing Monday it is bringing on a DLA Piper patent litigation attorney as a partner in its San Francisco office.

  • December 01, 2025

    MVP: Sidley's Sally Wagner Partin

    Sally Wagner Partin of Sidley Austin LLP represented Stryker Corp. in its $4.9 billion acquisition of the maker of medical technology used to remove blood clots without the need for clot-dissolving drugs, earning her a spot as one the 2025 Law360 Life Sciences MVPs.

  • December 01, 2025

    Meet The Attys Arguing Gov't Subpoena Power At High Court

    Law360 introduces the lawyers appearing at the U.S. Supreme Court on Tuesday in a case focused on an anti-abortion crisis center and a state attorney general's attempt to subpoena details on its donors.

  • December 01, 2025

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court saw a slate of corporate law clashes this past week, from fast-moving injunction fights in consumer product and real estate markets to multibillion-dollar oversight claims against crypto executives and fresh battles over control for two sports teams.

  • November 26, 2025

    Health Plans Defend Renewed Biogen MS Drug Scheme Suit

    Health plans claiming Biogen Inc. illegally stifled competition for its multiple sclerosis drug Tecfidera have said an Illinois federal judge should let their latest complaint proceed to discovery because it fixes earlier pleading deficiencies and better outlines the drugmaker's allegedly anticompetitive scheme.

  • November 26, 2025

    Calif. Cannabis Workers Settle Suit Over Quotas, Lack Of Pay

    Hourly agricultural laborers who accused California cannabis company Glass House Brands Inc. and some of its subsidiaries of bilking them out of sick pay, minimum wage and lunch breaks while enforcing quotas have agreed to settle what is left of their state court labor violation lawsuit for $305,000.

  • November 26, 2025

    Paratek Beats Suit Alleging $462M Sale Built On D&O Interests

    A Delaware vice chancellor tossed investor challenges to Paratek Pharmaceuticals' $462 million sale to Gurnet Point Capital and Novo Holdings, saying it was not reasonably conceivable that directors and officers undermined better deal prospects in order to protect personal interests.

  • November 26, 2025

    GTCR Drops FTC Constitutional Challenge Over Merger Case

    GTCR BC Holdings LLC has agreed to dismiss its constitutional claims against the Federal Trade Commission after enforcers dropped their case challenging the private equity firm's $627 million purchase of medical device coatings company Surmodics Inc.

  • November 26, 2025

    Avantor Sued Over Supply Chain Issues After $6.4B Deal

    Investors have accused executives at Pennsylvania-based laboratory supplier Avantor Inc. of falsely inflating the company's stock value by continually touting the value of its $6.4 billion merger with a major distributor in 2017, even as its failures to maintain its supply chain mounted, according to a proposed class action filed Tuesday in federal court.

  • November 26, 2025

    MVP: Ropes & Gray's Abigail Gregor

    Abigail Gregor of Ropes & Gray LLP advised Bain Capital on the formation of a new biopharmaceutical company focused on autoimmune disease treatments and AbbVie on its acquisition of a cell therapy developer in a potentially $2.1 billion deal, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.

  • November 26, 2025

    Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight

    A New Jersey federal judge on Wednesday tossed a lawsuit against Amarin Pharmaceuticals Inc. from its former CEO over his removal, finding that the allegations did not amount to "good cause" under Swiss law and that no qualifying "change of control" occurred to trigger severance benefits.

  • November 26, 2025

    Yale Healthcare Workers Lose COVID Vaccine Mandate Suit

    A Connecticut federal judge has again thrown out a complaint brought by several current and former Yale New Haven Health Services Corp. workers, who alleged the healthcare system's COVID-19 vaccine mandate violated their constitutional rights, finding they "have failed to plausibly allege sufficient facts that YNHHS acted under color of state law."

  • November 26, 2025

    Abbott Accused Of Miscalculating Workers' Overtime

    Abbott Laboratories miscalculated employees' overtime by failing to include periodic award pay in the regular rate of pay when they worked more than 40 hours per week, a former employee said in a proposed collective action in Illinois federal court.

  • November 25, 2025

    UnitedHealth Gets OptumRx Antitrust Suit Sent To Arbitration

    A group of independent pharmacies must arbitrate their proposed class claims that UnitedHealth-owned OptumRx gatekeeps its network of Medicare prescription patients by imposing unfair fees, a Washington federal judge said Tuesday, concluding the pharmacies haven't shown the arbitration clauses in question are unenforceable.

  • November 25, 2025

    Medical AI Co. Accused Of 'Smear Campaign' Against Rivals

    Two rivals of medical artificial intelligence platform OpenEvidence have told a Massachusetts federal judge the startup has used the courts in a campaign of "deceit, harassment and defamation" against competitors.

  • November 25, 2025

    Investors Say Alexandria Overhyped Leasing, NYC Project

    Alexandria Real Estate Equities Inc. investors filed suit in California federal court Tuesday, claiming the real estate investment trust overstated the strength of its leasing business and the projected value of a New York City property, causing the company's stock price to drop once the truth came to light.

  • November 25, 2025

    Mich. Pharmacist Gets 46 Months For $4M Fraud Scheme

    A former Michigan pharmacist who pled guilty to orchestrating a $4 million Medicare scam was sentenced by a federal judge to 46 months in prison and ordered to pay restitution and forfeit property as part of a plea deal, the U.S. Department of Justice announced.

  • November 25, 2025

    Judge Hands SEC Win In Pharma Co.'s CBD Investor Fraud Case

    A California federal judge has granted the U.S. Securities and Exchange Commission an early win in its suit against Vivera Pharmaceuticals, its CEO and affiliate Sentar Pharmaceuticals, finding they misled investors about the company's rights to key cannabinoid drug-delivery technology and about how investor money would be spent.

  • November 25, 2025

    MVP: Hogan Lovells' Mahvesh A. Qureshi

    Mahvesh A. Qureshi, a life sciences partner at Hogan Lovells, advised her client through a deal to acquire Anthos Therapeutics, a biopharmaceutical company that developed a unique stroke treatment, in a transaction that could total $3.1 billion, and led Merck on its up to $1.3 billion purchase of a novel autoimmune drug, earning her a spot as one of the 2025 Law360 Life Sciences MVPs.

  • November 25, 2025

    NRDC Tells 9th Circ. EPA Would 'Neuter' Public TSCA Rights

    The Natural Resources Defense Council has asked the Ninth Circuit to reject the U.S. Environmental Protection Agency's narrow reading of citizen enforcement rights under the Toxic Substances Control Act, saying it would unfairly restrict challenges to agency inaction.

  • November 24, 2025

    Mass. Judge Says States Can Fight Planned Parenthood Cuts

    A Massachusetts federal judge on Monday chided a Trump administration lawyer for continuing to argue that a coalition of states lacks standing to seek to block what it says is the effective defunding of Planned Parenthood, even as it only just received a lengthy list of new requirements for Medicaid reimbursement.

Expert Analysis

  • Insights From Recent Cases On Navigating Snap Removal

    Author Photo

    Snap removal, which allows defendants to transfer state court cases to federal court before a forum defendant is properly joined and served, is viewed differently across federal circuits — but keys to making it work can be drawn from recent decisions critiquing the practice, say attorneys at Perkins Coie.

  • Opinion

    It's Time For The Judiciary To Fix Its Cybersecurity Problem

    Author Photo

    After recent reports that hackers have once again infiltrated federal courts’ electronic case management systems, the judiciary should strengthen its cybersecurity practices in line with executive branch standards, outlining clear roles and responsibilities for execution, says Ilona Cohen at HackerOne.

  • Series

    Writing Novels Makes Me A Better Lawyer

    Author Photo

    Writing my debut novel taught me to appreciate the value of critique and to never give up, no matter how long or tedious the journey, providing me with valuable skills that I now emphasize in my practice, says Daniel Buzzetta at BakerHostetler.

  • SDNY OpenAI Order Clarifies Preservation Standards For AI

    Author Photo

    The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.

  • What 9th Circ.'s Rosenwald Ruling Means For Class Actions

    Author Photo

    The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.

  • Trends In Post-Grant Practice Since USPTO Denial Guidance

    Author Photo

    Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.

  • USPTO Under Squires: A Look At The First Month

    Author Photo

    New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.

  • Opinion

    Expert Reports Can't Replace Facts In Securities Fraud Cases

    Author Photo

    The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.

  • Opinion

    High Court, Not A Single Justice, Should Decide On Recusal

    Author Photo

    As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Series

    Traveling Solo Makes Me A Better Lawyer

    Author Photo

    Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.

  • Latest PTAB Moves Suggest A Subtle Recalibration

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.

  • Opinion

    DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable

    Author Photo

    In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.

  • Del. Ruling Reaffirms High Bar To Plead Minority Control

    Author Photo

    The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.

  • Series

    Law School's Missed Lessons: Client Service

    Author Photo

    Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.

  • How Occasional Activists Have Reshaped Proxy Fights

    Author Photo

    The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.